AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Globus Medical sees FYT adj EPS $3.00 to $3.30, est. $3.15
ByAinvest
Monday, Jul 21, 2025 8:06 am ET1min read
Globus Medical sees FYT adj EPS $3.00 to $3.30, est. $3.15
Globus Medical, Inc. (NYSE: GMED) has revised its full-year adjusted earnings per share (EPS) guidance for fiscal year 2025. The company now expects EPS to range between $3.00 and $3.30, down from the previously estimated $3.10 to $3.40 [2]. This adjustment follows the company's first-quarter 2025 earnings report, which showed a 1.4% year-over-year decrease in worldwide net sales to $598.1 million [2].Despite the weaker-than-expected Q1 results, Globus Medical maintained its full-year revenue guidance of $2.80 to $2.90 billion. The company attributed the first-quarter decline to softer Enabling Technology sales, temporary supply chain disruptions, and delayed international orders [2]. However, the US spine business remained strong, offsetting some of the decline.
Analysts remain bullish on the company's prospects. Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Globus Medical with a price target of $80, despite the company's recent financial performance [1]. The analyst noted that the company's US sales were steady, and the main reasons for weaker sales were fewer enabling technology deals and supply chain issues.
Globus Medical's latest product launches, such as the DuraPro™ Oscillating System and the COHERE™ ALIF Spacer, aim to enhance surgical precision and patient outcomes [2]. These innovations are part of the company's broader strategy to expand its portfolio of enabling technologies.
The company also announced a significant share repurchase program worth $500 million to address the disconnect between its intrinsic value and current market valuation [2]. The repurchase program will be funded through cash reserves and has no time limit.
Globus Medical is expected to discuss these developments during its first-quarter earnings conference call on May 8, 2025, after market close [2].
References:
[1] https://finance.yahoo.com/news/piper-sandler-maintained-buy-rating-143844171.html
[2] https://www.stocktitan.net/news/GMED/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet